News

NACDS lauds Senate passage of bipartisan bill to battle organized retail crime

BY Antoinette Alexander

ALEXANDRIA, Va. — In a statement issued on Monday, the National Association of Chain Drug Stores applauded the U.S. Senate for its passage of the “Strengthening and Focusing Enforcement to Deter Organized Stealing and Enhance Safety Act of 2012,” also known as the “Safe Doses Act” (H.R. 4223 and S. 1002).  

The bill passed unanimously in the Senate on Sept. 22, and previously passed in the U.S. House of Representatives on June 26.

This bipartisan legislation — supported by NACDS — will provide law enforcement with tools to break up sophisticated crime rings that harm consumers.  
 
These organized retail crime rings attempt to resell stolen medical products on the black market, including prescription drugs, biologicals, devices and infant formula.  Consumers are placed at risk when these stolen products are stored under unsafe conditions or otherwise tampered with, and then sold on the black market, including by illegal Internet drug sellers, NACDS stated.  
 
“Community pharmacy considers itself a partner in helping law enforcement curb criminal activities that can compromise consumer safety,” stated NACDS president and CEO Steve Anderson.  “This legislation empowers law enforcement to combat the serious problem of organized theft of medical products and bring down these illegal operations.”  
 
“We thank the sponsors of the Senate and House versions of this bill — U.S. Senator Charles Schumer, D-N.Y., and U.S. Rep. James Sensenbrenner, R-Wisc. — for their leadership in passing these bills to help keep consumers safe, and urge President Obama to expedite signing this important bill into law.” Anderson stated.
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

Coming out of summer, Alli returns to store shelves

BY Michael Johnsen

LEBANON, Pa. — Alli, pictured here at a CVS, is back on shelf. Supply issues earlier this year took many facings of GlaxoSmithKline’s Alli nonprescription weight loss solution out of play, but no longer, as of earlier this summer. With Alli’s absence, the hefty weight-loss solution fell behind Hydroxycut Advanced in number of units sold but still led all diet aids in sales with an 18.2% dollar share (to Hydroxycut Advanced’s 9.6%). Sales of diet aid tablets dropped 5.5%, to $218.9 million for the 52 weeks ending April 15 across food, drug and mass outlets (excluding Walmart), so you can expect those comp numbers to show a marked improvement in January with the 2013 spate of New Year’s Resolutions.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

FDA creates antibiotic development task force

BY Alaric DeArment

SILVER SPRING, Md. — The Food and Drug Administration is creating a new task force to support the development of new drugs for bacterial infections, the agency said Monday.

The FDA said the Antibacterial Drug Development Task Force would assist in developing and revising guidance related to development of antibiotics, as required by the Generating Antibiotic Incentives Now Title of the FDA Safety and Innovation Act, which president Barack Obama signed into law on July 9.

"The creation of this new task force comes at a critical time," FDA Office of Antimicrobial Products director Edward Cox said. "Establishing new ways of developing safe and effective new antibacterial drugs is an enormous challenge and not an effort that can be accomplished alone."

According to the agency, research and development for new antibacterial drugs has been in decline in recent decades, as has the number of new antibiotics approved by the FDA, which has been falling since the 1980s. At the same time, overuse of antibiotics has reduced their effectiveness and resulted in antibiotic-resistant bacteria.

More than 70% of the bacteria that cause hospital-associated infections are resistant to at least one type of commonly used antibiotic. Nearly 2 million people in the United States developed such infections in 2002, and 99,000 died.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?